Validation of Addenbrooke’s cognitive examination III for detecting mild cognitive impairment and dementia in Japan

BMC Geriatrics

Megumi Yamaguchi¹  Makiko Horiuchi¹  Norihito Yamada¹  Osamu Yokota¹  Seishi Terada¹  Nao Imai¹  Hidenori Yoshida¹  Tomoko Miki¹  Mayumi Yabe¹  Shintaro Takenoshita¹ 

[1] Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences;

关键词: Addenbrooke’s cognitive examination;    Cognitive screening;    Diagnosis dementia;    Diagnosis mild cognitive impairment;    Mild cognitive impairment;   

DOI  :  10.1186/s12877-019-1120-4

来源: DOAJ

【 摘 要 】

Abstract Background Early detection of mild cognitive impairment (MCI) and dementia is very important to begin appropriate treatment promptly and to prevent disease exacerbation. We investigated the screening accuracy of the Japanese version of Addenbrooke’s Cognitive Examination III (ACE-III) to diagnose MCI and dementia. Methods The original ACE-III was translated and adapted to Japanese. It was then administered to a Japanese population. The Hasegawa Dementia Scale-revised (HDS-R) and Mini-mental State Examination (MMSE) were also applied to evaluate cognitive dysfunction. In total, 389 subjects (dementia = 178, MCI = 137, controls = 73) took part in our study. Results The optimal ACE-III cut-off scores to detect MCI and dementia were 88/89 (sensitivity 0.77, specificity 0.92) and 75/76 (sensitivity 0.82, specificity 0.90), respectively. ACE-III was superior to HDS-R and MMSE in the detection of MCI or dementia. The internal consistency, test-retest reliability, and inter-rater reliability of ACE-III were excellent. Conclusions ACE-III is a useful cognitive test to detect MCI and dementia. ACE-III may be widely useful in clinical practice.

【 授权许可】

Unknown